Biogen Inc.

BIIB

Statistics

$335.95Share Price
$71.2 BMarket Cap
6.3%EBIT / EV
4.8%FCF / EV
33.1%ROIC
25.4%Cash ROIC
21.5%3yr Avg Revenue Growth
2.19Current Ratio
star logo

Business Model Diligence

We do not yet have Business Model Diligence for this stock.

Statistical Diligence

check mark The EBIT / Enterprise Value of 6.3% ranks as Above Average.
check mark The Free Cash Flow / Enterprise Value of 4.8% ranks as Above Average.
check mark The Return on Invested Capital Value of 33.1% ranks as Very High.
check mark The Cash Return on Capital Value of 25.4% ranks as Very High.
check mark The 3 Year Average Revenue Growth Value of 21.5% ranks as Above Average.
check mark Near-term Financial Health appears to be Very Good. The Current Ratio is 2.19.

Company Description

Biogen, Inc. is a global biotechnology company, which focuses on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. Its products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, and FAMPYRA for multiple sclerosis, ALPROLIX for hemophilia B and ELOCTATE for hemophilia A. The company also collaborates on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is approved for the treatment of chronic lymphocytic leukemia. Biogen was founded by Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Calculations

You must have a MagicDiligence Membership to view the Calculations for this stock. If you are already a member, you need to log in first.
Tracking Portfolios
blue wand Magic Recipe 29.36%
purple wand Deep Value 24.71%
orange wand Quality Growth 44.22%
green wand Green Team 6.14%
red dot Red Rating 5.76%
yellow dot Yellow Rating 14.17%
green dot Green Rating 14.95%
New Spell Stocks
blue wand Vector Group Ltd. (VGR)
purple wand New Stocks Added!